Skip to main content
. 2012 Jul 27;17(8):1014–1026. doi: 10.1634/theoncologist.2012-0043

Table 4.

Phase II and III randomized trials of everolimus in metastatic breast cancer

graphic file with name onc00812-1129-t04.jpg

aPhase II trial.

Abbreviations: BOLERO, Breast Cancer Trials of Oral Everolimus; CB, clinical benefit (6 months without progression); CI, confidence interval; HR, hazard ratio; mPFS, median progression-free survival; mTTP, median time to progression; ORR, overall response rate; OS, overall survival; TAMRAD, Tamoxifen and RAD001.